DS 1093

Drug Profile

DS 1093

Alternative Names: DS-1093; DS-1093a

Latest Information Update: 13 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Daiichi Sankyo Company
  • Class Antianaemics
  • Mechanism of Action Hypoxia-inducible factor-proline dioxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Anaemia

Most Recent Events

  • 29 Jan 2016 Discontinued - Phase-I for Anaemia in Hungary, United Kingdom, Hungary, Czech Republic (PO)
  • 01 Mar 2015 Daiichi Sankyo completes a phase I trial in Anaemia (in patients with chronic kidney disease) in Czech Republic and Hungary (NCT02299661)
  • 01 Feb 2015 Daiichi Sankyo completes a phase I trial in Anaemia (in volunteers) in United Kingdom (NCT02142400)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top